Bristol-Myers Squibb Company (NYSE: BMY) is one of the stocks Jim Cramer recently shed light on. When a caller noted that the ...

Even though oncology segment revenue inched up just 1 percent year over year, the firm lifted full-year expectations slightly ...

With a 5.98% market share, India is the fourth-largest pharmaceutical supplier to the U.S., behind Ireland, Switzerland, and ...

The objective response rate (ORR) was 32% with adagrasib versus 9% with docetaxel (OR 4.68, 95% CI 2.56-8.56, P <0.0001), ...

The growing healthcare burden posed by hepatocellular carcinoma, the most common subtype of liver cancer, has prompted the ...

Last week, President Trump sent letters to 17 major pharmaceutical companies advising them to work with his administration to ...

AI's fiscal 2025 momentum, fueled by surging Generative AI deployments, sets the stage for projected double-digit revenue growth in 2026.

Gilead Sciences generates stellar profit margins with its HIV and hepatitis C virus, or HCV, portfolio, which requires only a small salesforce and inexpensive manufacturing. We think its portfolio and ...

US healthcare stocks struggle in 2025 due to government policies, sparking interest from bargain hunters as valuations reach ...

Flaws remain for office in the San Francisco Peninsula office — but demand is starting to improve, as net absorption was -406 ...

Key Points On July 22, 2025, the U.S. Food and Drug Administration issued a Complete Response Letter for RP1, delaying potential commercialization and revenue. Research and development expenses ...

Patients with inflammatory bowel disease (IBD) have a 48% greater relative risk of developing interstitial lung disease (ILD) ...